Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

425 - Mast cells expressing the major source of interleukin 17 predict a favorable prognosis in hepatocellular carcinoma


19 Dec 2015


Poster presentation 1


Jian-fei Tu


Annals of Oncology (2015) 26 (suppl_9): 153-155. 10.1093/annonc/mdv534


J. Tu1, J. Ji2

Author affiliations

  • 1 Radilolgy, lishui central hospital, 323000 - lishui/CN
  • 2 Radiology, lishui central hospital, li shui/CN


Abstract 425


Interleukin (IL)-17 is expressed in the tumor micro-environment where it appears to contribute to tumor development. In hepatocellular carcinoma (HCC) studies, IL-17 has been associated with poor prognosis. However, the source of the increased tumor-infiltrating IL-17 in HCC and prognostic valve remain poorly understood.


59 HCC patients were enrolled in this study, immunofluorescence double stainwas used to evaluate the colocalization of CD3+ T cells, CD4+ T cells, CD56+ NK cells, CD20+ B cells, CD68+ Macrophages, and mast cell tryptase+ mast cells (MCT+ mast cells) with IL-17. The prognostic effect of groups with high and low MCT numbers was evaluated by Kaplan-Meier analysis and Cox regression model.


MCT+ mast cells, but not other cells, were the predominant IL-17-producing cell type. In HCC patients, immunofluorescence double stain showed a positive correlation between the number of MCT+ mast cells and microvessels (MCVs) and the majority of vascular endothelial cells expressing IL-17 receptor (IL-17R). Overall survival analysis revealed that the increasing intratumoral infiltrated MCT+ mast cells were significantly associated with a poor prognosis.


These findings indicated the major source of IL-17 in HCC were MCT+ mast cells and these cells infiltration may promote tumor progression by enhancing angiogenesis through the axis of IL-17/IL-17R. Increased IL-17-positive MCT+ mast cells was associated a poor prognosis, indicating therapy targeting MCT+ mast cells might be an effective strategy in controlling intratumor IL- 17 infiltration and MCVs.

Clinical trial identification



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings